Marvitense 40/5/12.5 Mg 30 Tablets

Marvitense 40/5/12.5 Mg 30 Tablets

Description:

Marvitense 40/5/12.5 mg 30 tablets is a prescription antihypertensive medicine that combines three active ingredients: olmesartan medoxomil, amlodipine, and hydrochlorothiazide. It is used for the treatment and long‑term control of high blood pressure (hypertension) in adults who require combination therapy to achieve adequate blood pressure reduction. By targeting blood pressure through three complementary mechanisms—angiotensin II receptor blockade, calcium channel blockade, and diuretic effect—Marvitense helps lower elevated blood pressure, reduce cardiovascular risk, and support heart and vascular health when used as directed by a physician.

Indications:

• Treatment of essential (primary) hypertension in adults.
• Patients whose blood pressure is not adequately controlled with dual therapy (e.g., olmesartan/amlodipine, olmesartan/hydrochlorothiazide, or amlodipine/hydrochlorothiazide) and who require triple combination therapy.
• Management of high blood pressure to help reduce the risk of cardiovascular complications such as stroke, heart attack, and kidney damage in appropriately selected patients.
• Control of symptoms and complications related to uncontrolled hypertension, such as persistent elevated blood pressure readings, headache, and increased cardiovascular strain (as part of a comprehensive treatment plan).

Active Ingredients / Key Components:

• Olmesartan medoxomil – 40 mg per film‑coated tablet (angiotensin II receptor blocker – ARB).
• Amlodipine (as amlodipine besylate or equivalent) – 5 mg per film‑coated tablet (dihydropyridine calcium channel blocker).
• Hydrochlorothiazide – 12.5 mg per film‑coated tablet (thiazide diuretic).
• Excipients: Film‑coating and tablet core excipients (such as fillers, binders, disintegrants, colorants, and stabilizers) are present; the exact full excipient list and their concentrations , please check the product leaflet or the manufacturer’s official website. Refer to the official package insert for a complete ingredient list.

Dosage & Administration / How to Use:

• Marvitense 40/5/12.5 mg is for oral use only and should be taken exactly as prescribed by your physician.
• Usual adult dose: One tablet once daily, preferably at the same time each day. The exact dose and strength are determined by the doctor based on blood pressure response and clinical condition.
• Swallow the tablet whole with a sufficient amount of water. Do not crush, chew, or break the film‑coated tablet unless advised by your doctor.
• Can be taken with or without food; taking it at the same time daily helps improve adherence.
• If a dose is missed, take it as soon as you remember on the same day. If it is almost time for the next dose, skip the missed dose and resume your regular schedule. Do not double the dose to make up for a missed tablet.
• Do not stop taking Marvitense suddenly without consulting your doctor, as this may lead to a rise in blood pressure and increased cardiovascular risk.
• Regular monitoring of blood pressure, kidney function, and electrolytes (especially potassium, sodium) is recommended during treatment.

Clinical Benefits:

• Provides potent blood pressure reduction by combining three complementary antihypertensive mechanisms in a single tablet, improving treatment effectiveness.
• Olmesartan blocks the vasoconstrictor and aldosterone‑secreting effects of angiotensin II, leading to vasodilation and reduced blood pressure.
• Amlodipine acts directly on vascular smooth muscle to cause peripheral arterial vasodilation, lowering peripheral vascular resistance and helping to control hypertension.
• Hydrochlorothiazide increases excretion of sodium and water by inhibiting sodium reabsorption in distal renal tubules, reducing blood volume and contributing to blood pressure lowering.
• Triple combination in one tablet may improve patient adherence compared to taking multiple separate medications, supporting long‑term blood pressure control.
• Helps reduce the risk of hypertension‑related complications such as stroke, heart failure, myocardial infarction, and kidney damage when used as part of a comprehensive cardiovascular risk management plan.

Warnings & Contraindications:

• Contraindicated in patients with known hypersensitivity to olmesartan, amlodipine, hydrochlorothiazide, other sulfonamide‑derived drugs, or any component of the formulation.
• Contraindicated during pregnancy, especially in the second and third trimesters, due to risk of fetal injury and death associated with drugs acting on the renin‑angiotensin system. If pregnancy is detected, discontinue Marvitense as soon as possible.
• Contraindicated in severe renal impairment, anuria, or severe hepatic impairment unless specifically evaluated and supervised by a specialist.
• Use with caution in patients with kidney disease, liver disease, heart failure, coronary artery disease, aortic stenosis, hypertrophic cardiomyopathy, electrolyte disturbances (such as low potassium, low sodium), gout, or diabetes.
• Hydrochlorothiazide may cause electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia) and may increase uric acid and blood glucose levels; regular monitoring is recommended in high‑risk patients.
• Amlodipine may cause peripheral edema and should be used cautiously in patients with heart failure or significant valvular disease.
• Olmesartan and other ARBs may affect kidney function, particularly in patients with renal artery stenosis or pre‑existing kidney disease; monitoring of renal function is advised.
• May cause symptomatic hypotension, especially in volume‑depleted patients (e.g., on high‑dose diuretics, low‑salt diet, vomiting, diarrhea). Initiate therapy carefully and monitor blood pressure.
• Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding, or if you are taking other medications such as other antihypertensives, diuretics, NSAIDs, lithium, or antidiabetic drugs.
• Not intended to diagnose, treat, cure, or prevent any disease without medical supervision; it is a prescription‑only medicine and must be used under the guidance of a healthcare professional.
• Keep out of reach of children.
• Do not drive or operate machinery if you feel dizzy, light‑headed, or fatigued after taking this medicine.

Side Effects:

• Common side effects may include dizziness, headache, fatigue, flushing, ankle or leg swelling (peripheral edema), palpitations, and mild gastrointestinal discomfort (nausea, abdominal pain).
• Hydrochlorothiazide‑related effects may include increased urination, electrolyte disturbances (low potassium, low sodium), increased uric acid (which may trigger gout in susceptible individuals), and slight increases in blood glucose or cholesterol levels.
• Less common side effects can include low blood pressure (hypotension), muscle cramps, rash, or allergic reactions.
• Serious but rare side effects may include severe hypotension, severe allergic reactions (angioedema, difficulty breathing, swelling of face, lips, or tongue), significant kidney function deterioration, chest pain, or irregular heartbeat. Seek immediate medical attention if these occur.
• If you experience persistent or bothersome side effects, contact your doctor or pharmacist for advice.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children.

Specifications:

• Product type: Prescription antihypertensive medicine (triple combination).
• Strength per tablet: olmesartan medoxomil 40 mg + amlodipine 5 mg + hydrochlorothiazide 12.5 mg.
• Form: Film‑coated tablet for oral use.
• Pack size: 30 tablets per pack.
• Intended use: Adult patients requiring combination therapy for the management of high blood pressure.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.